Skip to main content
. 2022 Sep 27;57(2):370–386. doi: 10.1002/jmri.28431

FIGURE 9.

FIGURE 9

18F‐FDG (left) and 89Zr‐trastuzumab PET scans (right) of three patients: Example of a patient with a 89Zr‐trastuzumab PET scan considered HER2‐positive (a), a 89Zr‐trastuzumab PET scan considered HER2‐negative (b), and an 89Zr‐trastuzumab PET scan considered equivocal (c). Reprinted under a Creative Commons (CC BY 4.0) license from: Bensch F, Brouwers AH, Lub‐de Hooge MN, de Jong JR, van der Vegt B, Sleijfer S, de Vries EGE, Schröder CP. 89Zr‐trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. Eur J Nucl Med Mol Imaging. 2018;45(13):2300–2306.